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Abstract. the present study investigated whether a water-
soluble extract from the culture medium of Ganoderma 
lucidum (reishi) mycelia (MAK) is able to protect the small 
intestine against damage induced by anti-cancer drugs. 
six-week-old male B6c3F1/crlj mice were fed a basal diet 
(MF) alone or with various doses of MAK or Agarics blazei 
Murrill (AgA) beginning one week before treatment with the 
anti-cancer drugs. Mice were sacrificed 3.5 days after injec-
tion of the anti-cancer drug, the small intestine was removed 
and tissue specimens were examined for the regeneration 
of small intestinal crypts. In experiment 1, the number of 
regenerative crypts after the administration of 5-fluorouracil 
(5FU) intravenously (250 mg/kg) or intraperitoneally (250 or 
500 mg/kg) was compared after treatment with MAK or 
AGA. MAK protected against 5FU-induced small intestinal 
injury whereas AgA did not. In experiment 2, we investigated 
the protective effect of MAK against small intestinal injury 
induced by the anti-cancer drugs: UFT (tegafur with uracil; 
1,000 mg/kg, orally), cisplatin (CDDP; 12.5 and 25 mg/
kg, intraperitoneally), cyclophosphamide (CPA; 250 mg/kg, 
orally) and gefitinib (Iressa; 2,000 and 4,000 mg/kg, orally). 
UFT and CDDP decreased the number of regenerative crypts, 
but treatment with MAK attenuated the extent of UFT- or 
cDDP-induced small intestinal injury. cPA or Iressa plus 
MAK up-regulated crypt regeneration. the present results 
indicate that MAK ameliorates the small intestinal injury 
caused by several anti-cancer drugs, suggesting that MAK is a 
potential preventive agent against this common adverse effect 
of chemotherapy.
Introduction
Ganoderma lucidum (Fr.) Karst. (Polyporaceae) is a medicinal 
mushroom known to the Japanese as ‘rei-shi’ or ‘Mannentake’, 
and to the chinese as ‘lingzhi’. Its fruiting bodies have been 
used for their medicinal properties in traditional chinese 
medicine for over 2,000 years. the use of this mushroom for 
promotion of vitality and as an anti-aging agent is described 
in detail in the classic compendium of traditional chinese 
medicine shen nung Ben cao Jin (dated 206 B.c. - 8 A.D.). 
Furthermore, Ganoderma lucidum (G. lucidum) was used 
more recently in china and other oriental countries for the 
treatment of debility and weakness, hypertension, cardiovas-
cular disease, bronchitis, arthritis, neurasthenia, insomnia, 
hepatopathy, chronic hepatitis, nephritis, gastric ulcer, asthma, 
diabetes, altitude sickness, AIDs and cancer (1-3). of partic-
ular interest among the reported biological/pharmacological 
properties of G. lucidum are its anti-tumor activities, including 
cell cycle arrest, induction of apoptosis, inhibition of motility, 
anti-angiogenesis and anti-mutagenesis (3-9). the fruiting 
bodies and the mycelium of the mushroom have very similar 
compositions, but the mycelium contains several additional 
nutrients and beneficial components. Thus, the mycelium 
is considered to be the ‘essence’ of the mushroom organism 
and is consumed as a functional food. the use of mycelia of 
Ganoderma as a ‘designer food’ means that culture techniques 
for this organism are well established.
A water-soluble extract from the culture medium of 
G. lucidum (rei-shi) mycelia (MAK) after fermentation on 
a solid medium containing bagasse contains various types of 
substances, such as polysaccharides, proteins, water-soluble 
lignin and triterpenes. Previously, we reported that MAK 
shows preventive effects on the development of chemical 
carcinogen-induced aberrant crypt foci, colon adenomas, 
colon tumors and pulmonary adenocarcinomas in rats (10-13). 
Furthermore, we reported that MAK has protective effects 
against X-irradiation-induced small intestinal injury in mice 
(14). Many of the adverse effects of anti-cancer drugs also 
arise from the ability of these drugs to inhibit DnA synthesis 
and cell division in normal cells. thus, we hypothesized that 
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MAK is able to protect against small intestinal injury after 
chemotherapy. the present study was conducted to assess the 
effects of MAK and Agarics blazei on small intestinal injury 
after the administration of various types of anti-cancer drugs.
Materials and methods
Animals. two hundred and thirty 6-week-old male B6c3F1/
crlj mice (charles river Japan, Inc.) were used in the present 
study. They were housed five to a polycarbonate cage and 
kept under constant conditions of temperature (24±2˚C) and 
relative humidity (55±10%) with a 12-h light/dark cycle. The 
animals were maintained in accordance with the ‘guidelines 
for the Care and Use of Laboratory Animals’ established by 
the hiroshima University and fed a commercial diet (oriental 
Yeast Co. Ltd., Tokyo, japan) alone or with a 1.25, 2.5 or 5.0% 
(w/w) supplement of MAK or AgA. normal tap water was 
also provided ad libitum.
Anti-cancer drugs. Anti-cancer drugs were obtained as 
follows: 5FU (5-FU injection 250 Kyowa; Kyowa hakko Co., 
Ltd., Tokyo, japan), UFT (prepared by Taiho Pharmaceutical 
Co., Ltd., Tokyo, japan), CDDP (randa injection; nippon 
Kayaku Co., Ltd., Tokyo, japan), CPA (endoxan; shionogi 
Pharmaceutical co., ltd., osaka, Japan) and Iressa (Iressa 
tablets 250; AstraZeneca K.K., osaka, japan).
G. lucidum mycelia and Agarics blazei. A water-soluble 
extract from the culture medium of MAK was prepared by 
noda shokkin-Kogyo co., ltd. (chiba, Japan). In brief, MAK 
were cultured in a solid medium composed mainly of sugar-
cane bagasse for three months. the whole medium containing 
the mycelia was then extracted with hot water. the extract was 
filtered and spray-dried to obtain MAK. Agarics was purchased 
as a commercial powder of Agarics blazei Murrill.
Autopsy. Mice were sacrificed 3.5 days after injection of the 
anti-cancer drugs. Immediately after sacrifice, segments of the 
jejunum from the ileum junction (30-40 cm) were removed and 
fixed in Carnoy's solution. The segments were cut into several 
pieces, bundled together, embedded in paraffin, sectioned at 
a thickness of 3 µm and stained with hematoxylin and eosin. 
to quantify regenerating crypts, the number of crypts/circum-
ference was determined in cross-section. In each mouse, the 
number of regenerative crypts in 10 gut cross-sections was 
scored.
Experiment 1. this was a comparative study of the ability of 
MAK and AgA to attenuate the small intestinal injury induced 
by 5FU. Mice were fed a basal diet (MF) alone or with 1.25, 
2.5 or 5.0% of MAK or AGA beginning one week prior to 
treatment with the anti-cancer drug, which was administered 
intravenously (i.v.) (250 mg/kg) or intraperitoneally (i.p.) 
(250 or 500 mg/kg). At 3.5 days after the administration of 
5FU, the mice were sacrificed. body weight and organ weights 
of thymus, liver, kidney, spleen and testis were recorded, and 
the number of regenerative crypts of the small intestine was 
measured as described above.
Experiment 2. this was a study of the protective effect of 
MAK on small intestinal injury induced by several anti-cancer 
drugs. At one week after initiation of treatment with MAK, 
the anti-cancer drugs were administered as follows: cPA was 
given orally (p.o.; 250 mg/kg), i.p. (200 mg/kg) and subcutane-
ously (s.c.; 150 mg/kg). Iressa was p.o. as one dose (2,000 mg/
kg) or as two doses (4,000 mg/kg) with a 2-h interval between 
the doses. Mice were sacrificed at 3.5 days after the adminis-
tration of each anti-cancer drug. Body and organ weights and 
the number of regenerative crypts were measured.
Statistical analysis. statistical significance was determined 
by Dunnett's method for multiple comparisons.
Results
Experiment 1: Comparative study of the ability of MAK and 
AGA to attenuate 5FU-induced small intestinal injury. the 
administration of 5FU (250 mg/kg, i.v.) resulted in body weight 
and organ weight loss in spleen, liver, thymus and kidney, but 
not in testis (table I). treatment with MAK and AgA did not 
table I. Body and organ weights (relative weights).
Group bW (g) spleen (mg) Liver (g) Thymus (mg) Kidney (g) Testis (g)
normal 23.1±1.1 0.090±0.019 1.37±0.09 0.044±0.009 0.39±0.02 0.149±0.011
5% MAK  23.6±0.6a  0.095±0.017a  1.48±0.10a  0.050±0.009a  0.41±0.03a 0.148±0.017
5% AGA  24.1±1.6a  0.111±0.037a  1.48±0.12a  0.062±0.008a  0.41±0.03a 0.152±0.007
5FU + MF  21.1±1.5c  0.038±0.006c  1.18±0.16c  0.028±0.012d  0.32±0.02d 0.127±0.019
5FU + 5% MAK 21.3±1.2 0.042±0.003 1.19±0.09 0.022±0.004 0.34±0.02 0.114±0.027
5FU + 5% AGA 21.6±0.8 0.045±0.004 1.26±0.10 0.027±0.009  0.36±0.03b 0.134±0.023
5FU + 2.5% MAK 21.6±1.2 0.042±0.004 1.21±0.05 0.027±0.005  0.36±0.04b 0.132±0.019
5FU + 2.5% AGA 21.4±1.6 0.045±0.005 1.25±0.17 0.014±0.005  0.36±0.02b 0.133±0.018
5FU + 1.25% MAK 22.3±0.6 0.042±0.002 1.22±0.05 0.019±0.007  0.36±0.01b 0.127±0.021
5FU + 1.25% AGA 22.9±0.5 0.047±0.004 1.28±0.06 0.027±0.012  0.39±0.01a 0.147±0.005
values are mean ± sD. asignificant difference from the 5FU + MF value (p<0.01); bsignificant difference from the 5FU + MF value (p<0.05); 
csignificant difference from the normal value (p<0.05); dsignificant difference from the normal value (p<0.01).
oncology letters  1:  63-68,  2010 65
affect these weight losses, except that kidney weight loss was 
attenuated in the 5FU + MAK and 5FU + AGA groups, with 
the exception of 5FU + 5% MAK.
small intestine tissue specimens were prepared and 
counted for the number of regenerative crypts (table II). 
The administration of 5FU (250 mg/kg, i.v.) significantly 
decreased the number of regenerative crypts compared with 
the normal group (83.7±11.2 vs. 110.2±8.9, p<0.01). The 5FU 
+ MAK groups showed a significant increase compared 
with the 5FU-alone group (p<0.01), whereas treatment with 
table II. number of regenerative crypts.
Group   250 mg/kg i.v.    250 mg/kg i.p. 500 mg/kg i.p.
normal  110.2±8.9a    100.6±10.5a    100.6±10.5a
5% MAK  112.9±12.2 100.5±9.2 100.5±9.2
5% AGA  116.2±13.6   103.7±10.0   103.7±10.0
5FU + MF   83.7±11.2     89.1±11.0   67.7±8.2
5FU  +5% MAK  97.0±9.9a     106.6±16.6a    83.4±7.9a
5FU + 5% AGA  82.0±9.5    80.4±8.4     73.6±10.7
5FU + 2.5% MAK   110.3±14.3a     116.5±14.3a    82.8±7.9a
5FU + 2.5% AGA   87.6±14.9      89.6±11.2   70.9±8.1
5FU + 1.25% MAK  113.6±15.0a     118.1±15.3a   71.2±9.5
5FU + 1.25% AGA 85.5±9.9      87.3±10.8   73.4±7.9
values are mean ± sD. asignificant difference from the 5FU + MF value (p<0.01); i.v., intravenously; i.p., intraperitoneally.
Figure 1. effect of several anti-cancer drugs with or without MAK treatment on body weight in mice. Body weights were monitored daily for 3 days after the 
administration of individual anti-cancer drugs. Asterisks indicate significant differences between the individual anti-cancer drug + MF group vs. the normal 
group (*p<0.05, **p<0.01).
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5FU + AGA did not affect the number of regenerative crypts 
(82.0±9.5 to 87.6±14.9). The number of regenerative crypts 
significantly decreased after treatment with 5FU (250 mg/
kg, i.p.) compared with the normal group (89.1±11.0 vs. 
100.6±10.5, p<0.01). Again, the number of regenerative crypts 
in the 5FU + MAK groups (106.6±16.6 to 118.1±15.3) was 
significantly higher than that in the 5FU-alone group (p<0.01), 
whereas treatment with 5FU + AGA did not affect the number 
of regenerative crypts (80.4±8.4 to 89.6±11.2). Administration 
of 5FU (500 mg/kg, i.p.) resulted in a significant decrease in 
the number of regenerative crypts compared with the normal 
group (67.7±8.2 vs. 100.6±10.5, p<0.01). This decrease in the 
number of regenerative crypts was significantly attenuated in 
the 5FU + 5% MAK and 5FU + 2.5% MAK groups compared 
with the 5FU-alone group (83.4±7.9 and 82.8±7.9, p<0.01), 
whereas the 5FU + AGA and 5FU + 1.25% MAK groups 
showed no such effect (70.9±8.1 to 73.6±10.7). small intestinal 
crypt regeneration was unaffected by MAK or AgA alone.
Experiment 2: Protective effect of MAK on small intestinal 
injury induced by several anti-cancer drugs. Fig. 1 shows 
body weight changes of mice administered with UFT 
1,000 mg/kg (p.o.), CDDP 25 mg/kg (i.p.), CPA 250 mg/
kg (p.o.) or Iressa 4,000 mg/kg (p.o.). The administration of 
UFT or CDDP decreased the body weight from the following 
day, and administration of cPA decreased body weight after 
2 days, whereas the administration of Iressa had no effect on 
body weight. treatment with MAK did not alter the body 
weight loss or gain associated with administration of these 
anti-cancer drugs.
tissue specimens of the groups were prepared and counted 
to assess the number of regenerative crypts (table III). 
Following administration of UFT (1,000 mg/kg, p.o.), 
the number of regenerative crypts significantly decreased 
compared with the normal group (65.8±8.1 vs. 107.6±10.4, 
p<0.01). At all dose levels, treatment with MAK significantly 
increased the number of regenerative crypts compared with 
the UFT-alone group (80.6±11.4 to 102.7±2.5, a 22.5-56.1% 
up-regulation compared with UFT + MF, p<0.01). Following 
administration of CDDP (12.5 mg/kg, i.p.), the number of 
regenerative crypts significantly decreased compared with 
the normal group (89.8±11.7 vs. 107.6±10.4, p<0.01). The 
number of regenerative crypts in the CDDP + MAK groups 
showed a significant increase compared with the CDDP-alone 
group (117.4±16.7 to 121.7±12.6, a 30.7-35.4% up-regulation 
compared with CDDP + MF; p<0.01). The number of 
regenerative crypts after administration of CDDP (25.0 mg/
kg, i.p.) showed a significant decrease compared with the 
normal group (9.5±4.4 vs. 108.0±13.9, p<0.01). The number of 
regenerative crypts in the CDDP + MAK groups significantly 
increased compared with the CDDP-alone group (21.9±4.7 
to 32.5±3.4, a 130.5-242.1% up-regulation vs. CDDP + MF; 
p<0.01). Following administration of CPA (250 mg/kg, p.o.), 
the number of regenerative crypts significantly increased 
compared with the normal group (120.9±12.1 vs. 110.5±12.6, 
p<0.01) and this up-regulation was further increased by treat-
ment with MAK (136.6±13.8 to 150.0±14.7, a 13.0-24.1% 
increase vs. CPA + MF, p<0.01). The number of regenerative 
crypts after administration of cPA (200 mg/kg, i.p.) showed 
a significant increase compared with the normal group 
table III. effect of MAK on crypt regeneration after adminis-
tration of several anti-cancer drugs.
group no. of regenerative Increased
 crypts rate (%)
UFT 1,000 mg/kg p.o.
  normal 107.6±10.4
  UFT + MF 65.8±8.1
  UFT + 1.25% MAK    80.6±11.4a  (22.5)b
  UFT + 2.5% MAK    94.2±11.5a (43.2)
  UFT + 5.0% MAK  102.7±12.5a (56.1)
CDDP 12.5 mg/kg i.p.
  normal 107.6±10.4
  CDDP + MF  89.8±11.7
  CDDP + 1.25% MAK 117.4±16.7a (30.7)
  CDDP + 2.5% MAK 121.7±12.6a (35.4)
  CDDP + 5.0% MAK 118.4±14.6a (31.7)
CDDP 25 mg/kg i.p.
  normal 108.0±13.9
  CDDP + MF   9.5±4.4
  CDDP + 1.25% MAK 21.9±4.7a  (130.5)
  CDDP + 2.5% MAK 26.6±5.3a  (180.0)
  CDDP + 5.0% MAK 32.5±3.4a  (242.1)
CPA 250 mg/kg p.o.
  normal 110.5±12.6
  CPA + MF 120.9±12.1
  CPA + 1.25% MAK 136.6±13.8a (13.0)
  CPA + 2.5% MAK 148.7±15.0a (23.0)
  CPA + 5.0% MAK 150.0±14.7a (24.1)
cPA 200 mg/kg i.p.
  normal 107.4±9.7
  CPA + MF   135.5±13.6
  CPA + 1.25% MAK    145.1±16.3a   (7.1)
  CPA + 2.5% MAK    147.0±17.4a   (8.5)
  CPA + 5.0% MAK    152.2±17.2a (12.3)
CPA 150 mg/kg s.c.
  normal 107.4±9.7
  CPA + MF   117.8±14.9
  CPA + 1.25% MAK    130.4±13.8a (10.7)
  CPA + 2.5% MAK    150.6±17.0a (27.8)
  CPA + 5.0% MAK    160.4±17.1a (36.2)
Iressa 2,000 mg/kg p.o.
  normal 108.0±13.9
  Iressa + MF 107.5±11.7
  Iressa  +1.25% MAK  117.8±10.6a   (9.6)
  Iressa + 2.5% MAK  119.9±13.7a (11.5)
  Iressa + 5.0% MAK  123.6±14.7a (15.0)
Iressa 4,000 mg/kg p.o.
  normal 110.5±12.6
  Iressa + MF 110.0±11.8
  Iressa + 1.25% MAK  132.2±15.5a (20.2)
  Iressa + 2.5% MAK  151.5±16.9a (37.7)
  Iressa + 5.0% MAK  161.5±19.8a (46.8)
values are mean ± sD; p.o., given orally; i.p., intraperitoneally; s.c., 
subcutaneously. asignificantly different from the value for the indi-
vidual anti-cancer drug + MF group (p<0.01); bpercentage increase 
from the value for the individual anti-cancer drug + MF group.
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(135.5±13.6 vs. 107.4±9.7, p<0.01) and again this up-regulation 
was further increased by treatment with MAK (145.1±16.3 
to 152.2±17.2, a 7.1-12.3% increase vs. CPA + MF; p<0.01). 
Following administration of CPA (150 mg/kg, s.c.), the number 
of regenerative crypts was similar to that of the normal group 
(117.8±14.9 vs. 107.4±9.7), but treatment with MAK caused a 
significant up-regulation compared with the CPA-alone group 
(130.4±13.8 to 160.4±17.1, a 10.7-36.2% increase vs. CPA 
+ MF; p<0.01). The number of regenerative crypts after the 
administration of Iressa (2,000 mg/kg, p.o.) was similar to that 
of the normal group (107.5±11.7 vs. 108.0±13.9), but the Iressa 
+ MAK group showed a significant up-regulation compared 
with the Iressa-alone group (117.8±10.6 to 123.6±14.7, a 
9.6-15.0% increase vs. Iressa + MF; p<0.01). similarly, the 
number of regenerative crypts was unaffected by the adminis-
tration of Iressa (4,000 mg/kg, p.o.) (110.0±11.8 vs. 110.5±12.6 
in the normal group), but was significantly up-regulated in the 
Iressa + MAK group compared with the Iressa-alone group 
(132.2±15.5 to 161.5±19.8, a 20.2-46.8% increase vs. Iressa + 
MF; p<0.01).
histologically, no marked changes such as desquama-
tion, edema and/or necrosis were noted in the small intestine 
following the administration of cPA or Iressa.
Discussion
MAK prevented small intestinal injury by increasing the 
number of regenerative crypts, but had no effect on body 
weight loss induced by 5FU, UFT and CDDP. Wang et al 
reported that a G. lucidum extract ameliorated cDDP-induced 
nausea, vomiting and food intake in a concentration-dependent 
manner in a rat pica model measuring kaolin intake (15). In a 
clinical study reported by shu-ru et al, a chinese medicinal 
herb complex containing a G. lucidum extract decreased 
leucopenia and neutropenia induced by chemotherapy and/or 
radiotherapy (16). nonaka et al reported that an antlered form 
of G. lucidum (rokkaku-reishi) relieved cPA-induced weight 
loss, and suggested that G. lucidum is useful in reducing the 
adverse effects of anti-cancer drugs (17). Furthermore, nonaka 
et al reported that G. lucidum inhibited transplanted tumor 
growth, elongated life span when administered orally to mice 
(18) and showed anti-tumor activity when administered after 
tumor inoculation.
recently, we found that 5FU decreased the formation of 
aberrant crypt foci (AcF) induced by azoxymethane, and that 
combination with MAK further decreased the number of AcF 
(19). We suggested that MAK reduces the gastrointestinal 
adverse effects of anti-cancer drugs without attenuating their 
beneficial anti-tumor activity.
In the present experiment, MAK attenuated small intestinal 
damage caused by 5FU, whereas AGA did not. Further studies 
are required to elucidate the difference in the effects of mycelia 
and fruiting bodies, although we noted earlier that AgA does 
not protect against small intestinal damage by X-irradiation. 
We conclude that AGA is ineffective for the prevention of acute 
small intestinal injury. on the other hand, the present study 
showed that MAK is active against small intestinal injury 
induced by 5FU, UFT, CPA, Iressa and CDDP.
It is well established that, regardless of the administration 
route, the mechanism by which anti-cancer drugs such as 5FU, 
UFT and CDDP exert both their therapeutic and toxic effects is 
by inhibition of DnA synthesis. recently, tong et al reported 
that reishi increased the uptake of brdU in a mouse spleen 
cell cultivation system and promoted cell proliferation (20). 
In our study, the number of regenerative crypts increased by 
administration of cPA or Iressa plus MAK, but not of MAK 
alone. Furthermore, we observed no marked changes such as 
desquamation, edema and/or necrosis in the small intestine 
after administration of cPA or Iressa. clinically, small intes-
tinal injury was reported after administration of both cPA and 
Iressa (21). the reason that these two anti-cancer drugs did not 
affect small intestinal crypts in this experiment is not clear, but 
it is conceivable that they had some effect other than inhibition 
of DnA synthesis, since crypt regeneration was accelerated by 
MAK after administration of these agents. It is possible that 
MAK-induced crypt regeneration after administration of these 
drugs is a response to a mild injury that cannot be detected by 
microscopic observation.
taken together, the results suggest that reishi can 
immediately promote cell growth to repair acute injury 
caused by trauma such as X-irradiation and/or administration 
of chemotherapeutic drugs. recently, Fukatsu et al reported 
that 5FU influences gut-associated lymphoid tissue (known as 
gAlt) by reducing the number of lymphocytes in the small 
intestinal intraepithelial space and lamina propria (22). strober 
et al reported that the breakdown of gAlt may contribute to 
chronic inflammatory bowel disease, such as Crohn’s disease 
and ulcerative colitis (23). Previously, we found that MAK 
shows a preventive action on the Dss-induced mouse model 
of ulcerative colitis (unpublished data). In this context, the 
acceleration of regenerative crypt growth after administration 
of 5FU, UFT, CPA and Iressa suggests that MAK functions 
through a gAlt-mediated mechanism of action. It is thought 
that a part of the activity of rokkaku-reishi against the adverse 
effects of cPA may be mediated by its immunomodulating 
properties, such as natural killer activity, interferon-γ 
production, cytotoxic t-lymphocyte activity and inhibition 
of abnormal changes in the interleukin-4 level (17,18). We 
also previously reported that MAK has immunomodulating 
functions, such as the up-regulation of phagocytosis and nK 
activity and increased tnF-α production (24). Thus, if the 
administration of anti-cancer drugs such as cPA and Iressa 
induces immunological dysregulation in the gAlt, such effects 
may be reversed by the immunomodulatory action of MAK.
edema or cell infiltration of the fore-stomach and/or 
renal injury after administration of anti-cancer drugs were 
confirmed by the microscopic observations in this experiment, 
although MAK appeared to have little effect on these lesions 
(data not shown). conversely, omori et al reported that reishi 
reduced the renal disorder induced by CDDP (25). however, 
our study only had 3.5 day duration and the longer-term effect 
of MAK on injury to these organs needs to be established in 
further studies.
In conclusion, our results suggest that MAK ameliorates the 
small intestinal damage induced by cancer treatments such as 
radiotherapy and chemotherapy, thereby improving the quality 
of life of cancer patients. Further studies of longer duration are 
required to assess the value of this preparation in the treatment 
of other adverse effects of anti-cancer drugs, such as organ 
injury and alopecia.
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